1. 引言
Türkiye’s large and well-regulated pharmaceutical market presents lucrative opportunities for global manufacturers, wholesalers, and parallel importers. Its advanced logistics, regional export capacity, and robust compliance culture make Türkiye a strategic hub for medicine distribution. However, the sector is strictly regulated—with legal pitfalls for the unwary, especially around licensing, parallel import, and anti-counterfeiting.
This article provides a legal and practical guide for international companies on navigating medicine distribution, wholesale, and parallel import in Türkiye.
2. Legal Framework: Core Regulations and Authorities
a) 土耳其药品和医疗器械管理局 (TITCK)
- The main authority for authorizing wholesale activities, distribution channels, and parallel import.
- All wholesalers must be licensed, inspected, and compliant with GDP (Good Distribution Practices).
b) Key Laws and Regulations
- 药品和医疗制剂法（第1262号）
- Regulation on the Distribution and Wholesale of Medicinal Products for Human Use
- Competition Law and Customs Code
- Anti-Counterfeiting, Trademark and Patent Legislation
3. Wholesale and Distribution Licensing
- All wholesalers and distributors must obtain a license from TITCK.
- Physical warehouse, cold chain, and traceability systems (İlaç Takip Sistemi – ITS) are mandatory.
- Detailed documentation: company incorporation, GMP/GDP compliance, responsible technical staff, and security protocols.
- Foreign-owned entities can be licensed if they meet all conditions.
4. Parallel Import: Legal Opportunities and Constraints
a) What is Parallel Import?
- Importing branded medicines from other countries, where they are sold at lower prices, into Türkiye—without the brand owner’s permission.
- Legally possible under “international exhaustion” of trademark rights.
b) Regulatory Requirements
- Only medicines already authorized and registered in Türkiye can be parallel imported.
- Parallel import license is required from TITCK, with full product equivalence documentation.
- Packaging, labeling, and pharmacovigilance obligations apply just like original products.
c) Opportunities
- Cost savings for public and private buyers
- Supply chain flexibility, especially in cases of local shortages
- Competitive pricing—parallel imported medicines can drive down costs
d) Legal Risks and Limitations
- Brand owners may challenge on trademark, patent, or data exclusivity grounds.
- Any deviation in formulation, packaging, or documentation can result in product seizure or fines.
- Anti-counterfeiting controls are strict: serial tracking and verification via ITS is compulsory.
- Public tenders may exclude parallel imports for certain categories.
5. Practical Issues and Market Trends
- Distribution Agreements: Must comply with competition law (exclusive or selective distribution may raise scrutiny).
- Tendering: Public hospital tenders have complex requirements—local partners are essential.
- Supply Chain Security: Robust logistics, insurance, and IT systems are needed to prevent diversion and counterfeiting.
- Regulatory Inspections: TITCK regularly audits distributors and importers; non-compliance can mean loss of license.
6. Key Legal Risks for Foreign Investors
- License Revocation: Any breach of GDP, misreporting, or traceability failure can trigger immediate revocation.
- Trademark and Patent Litigation: Parallel importers must check for ongoing IP protection.
- Contractual Risk: Distribution agreements should clearly allocate liability, recall obligations, and dispute resolution.
7. Best Practices for Success
- Partner with experienced local wholesalers/distributors.
- Invest in compliance: traceability, pharmacovigilance, and anti-counterfeit protocols.
- Structure contracts with clear IP, liability, and compliance clauses.
- Monitor TITCK and competition authority for regulatory changes.
8. Why Legal Guidance is Crucial
Navigating the Turkish pharma distribution landscape without expert support is risky—regulations evolve, and authorities enforce compliance rigorously.
A knowledgeable legal team ensures you obtain and maintain your licenses, draft robust contracts, and mitigate IP and supply chain risks from day one.
Stj.Öğr.Esmanur AKTAŞ
暂无回复